How to determine medicines benefits policy and program needs?

Slides:



Advertisements
Similar presentations
MDG based national development strategies and plans in Africa: the role of the Integrated Package of Services Presentation by BDP/BRSP at RBA Workshop.
Advertisements

PAYING FOR PERFORMANCE In PUBLIC HEALTH: Opportunities and Obstacles Glen P. Mays, Ph.D., M.P.H. Department of Health Policy and Administration UAMS College.
Patients Perspective on UHC and Health Benefits Plans Eva Maria Ruiz de Castilla IAPO Board Member President, ESPERANTRA December 6, 2013 Washington, DC.
Towards a New R&D Strategy A blueprint for R&D in Health and Social Care Noreen Caine Deputy Director of R&D, DH NHS R&D Forum Annual Conference May 2005.
Public-Private Partnerships in Health Keerti Bhusan Pradhan
Health Systems and Actors Tom Merrick, World Bank.
World Health Organization
November Gap analysis – key factors  Alignment with needs  Quality of services  Cost of services  Risks in existing arrangements  Relationship.
MerSETA Strategic Plan Derrick Peo General Manager : Innovation, Research & Development.
Primary Health Care Strategy – Implementation Plan Stephen McKernan Director General of Health.
Aust. AM Collaborative Group (AAMCOG) An introduction to ISO “What to do” guide 20th October 2014.
Comparing health systems Week 19 Comparative Sociology.
BIG DATA AND THE HEALTHCARE REVOLUTION FORD+SSPG 2014.
Consultative Meeting on Accelerating the Attainment of MDG 5 in Kenya – August 27-28, 2014 Investing in Primary Health Care for reducing maternal & child.
Generating evidence for change: Implementing the post-ICIUM research agenda Dennis Ross-Degnan, ScD Harvard Medical School and Harvard Pilgrim Health Care.
STRENGTHENING HEALTH SYSTEMS Anne Mills DCPP Editor London School of Hygiene and Tropical Medicine.
UNDP & the Business SectorBureau for Resources and Strategic Partnerships Business, sustainable development and the MDGs: A changing landscape.
© 2010 Plexent – All rights reserved. 1 Change –The addition, modification or removal of approved, supported or baselined CIs Request for Change –Record.
Essential Service # 7:. Why learn about the 10 Essential Services?  Improve quality and performance.  Achieve better outcomes – improved health, less.
National Medicine Policy
Jobs Australia David Thompson. FIESS 2011 Montreal Supporting the Community Employment Sector in Australia David Thompson AM, CEO Jobs Australia and RIPESS.
Regulatory Transparency and Interaction with the Government Dr. Konstantin Petrov Head of Section, Policy and Regulation.
Dorcas Sithole Mental Health Department Ministry of Health & Child Welfare 1.
Medicines Transparency Alliance01/10/2015 Availability of Medicines Anita Wagner Harvard Medical School & WHO Collaborating Center in Pharmaceutical Policy.
Summary of ICIUM Chronic Care Track Prepared by: Ricardo Perez-Cuevas Veronika Wirtz David Beran.
Summary from the Economics Track With thanks to all track participants, presenters, rapporteurs, moderators and organizers.
Key issues in health care financing Di McIntyre. Objectives Introduce some key concepts Introduce a useful analytic framework Illustrate the analytic.
3 August 2004 Public Health Practice III: FINANCING PUBLIC HEALTH REFORM Thomas E. Novotny MD MPH University of California San Francisco Institute for.
Svetlana Spassova, MD Ministry of Health, Bulgaria Chisinau
Pharmaceutical system strengthening – Is there a need for a new paradigm? Andreas Seiter The World Bank ICIUM 2011, Antalya 1.
Engaging Communities and the Workforce through Co-production Gerry Power National Lead – Coproduction and Community Capacity Building Shifting the Focus.
Policy track summary ICIUM 2011 – 18 Nov Policy track topics 1.The pharmaceutical policy process 2.Quality and safety of medicines in LMIC 3.Policy.
Availability of children’s medicines in Africa, 2007 Jane Robertson, Gilles Forte, Suzanne Hill.
Opportunities to Integrate NCDs into Existing Systems Lessons Learned from the HIV-Experience Astrid Permin, Senior Technical Adviser, TAS.
Ministry of Healthcare & Nutrition Broader Approaches to Health Strategic Frame Work for Health Development.
WHO/OMS Improving and increasing investments in the health outcomes of the poor Macroeconomics and Health in context Dr. Sergio Spinaci, WHO Senegal, February.
Designing and Managing Medicines Benefits – Goals, Policy Options, Ethical Considerations Anita Katharina Wagner Department of Population Medicine Harvard.
WHO-Technical Briefing Seminar | October-November 2012 Dr Cécile Macé 1 |1 | Good Governance for Medicines Programme Dr Cécile Macé EMP/MPC.
Improving Total System Performance & Public-private Partnership Dr. FUNG Hong Hospital Authority May 2001.
High Level Policy Dialogue – Cambodia Towards a Strong and Sustainable Health Sector Development ( Health Strategic Plan) 24 June, 2015 Cambodia.
The PHRplus Project is funded by U.S. Agency for International Development and implemented by: Abt Associates Inc. and partners, Development Associates,
PRESENTATION TO PORTFOLIO COMMITTEE ON WATER AFFAIRS AND FORESTRY Cindy Damons 28 May 2008 The role of municipalities in managing and giving effect to.
Kathy Corbiere Service Delivery and Performance Commission
Financing for Reproductive, Mother, Newborn, Child, and Adolescent Health for UHC ACCELERATING PROGRESS ON EARLY ESSENTIAL NEWBORN CARE September,
Shaping the future Consultation on the Heritage Lottery Fund’s Strategy January – 26 April 2011.
Slide 1 Achieving National Quality Reporting Progress? Elliott S. Fisher, MD, MPH Professor of Medicine Center for the Evaluative Clinical Sciences Dartmouth.
SUPPLY SIDE POLICIES YOUSIF AL ZAROUNI. WHAT ARE SUPPLY SIDE POLICIES? Supply side policies are policies designed to improve the supply side potential.
Tertiary Education Agenda New Zealand July Key domestic issues Equity in achievement Demographic patterns Affordability for government Tight labour.
Ministry’s Vision for Universal Health Coverage Dr San San Aye Director (Planning) Department of Health Planning Ministry of Health National Dialogue on.
Overview. Basic functions  Revenue collection  Pooling of resources  Purchasing of services.
Dr. Carissa F. Etienne Director PAHO/WHO UNIVERSAL HEALTH COVERAGE Building a path forward in the Region of the Americas 3 December 2013.
The Workforce, Education Commissioning and Education and Learning Strategy Enabling world class healthcare services within the North West.
Advancing Partnerships for Universal Health Coverage HANSHEP Workshop Dr. Rehana Ahmed 9 July 2015 Nairobi 1.
Overview and Scrutiny, Coordinating and Call In Committee Personalisation Presentation 3 March 2009.
Coordination of health care in the EU Jakub Wtorek European Commission Directorate General for Employment, Social Affairs and Inclusion Unit: Active Ageing,
Susan Sparkes Department of Health System Governance and Financing, WHO Financing for universal health coverage: What does this mean for ending the HIV.
EDM Strategy for Working with Countries: the Uganda Example
Manchester Health and Care Commissioning Strategy
The continuum of care: The Role of Technology
Global Health Competencies for UK Healthcare Professionals
Overview of guidance/frameworks
Health Technology Assessment
Mapping of Objectives to Guiding Principles.
Musculoskeletal Health in Europe
Lecture 9: PHC As a Strategy For HP Dr J. Sitali
FOR UNIVERSAL HEALTH COVERAGE
Health Technology Assessment for Universal Health Coverage
Access to Essential Medicines
Do’s and Don’ts in light of recent changes
Impact of quality on day-to-day efforts of PHC
Presentation transcript:

How to determine medicines benefits policy and program needs?

What are the objectives of medicines benefit policies and programs on the path toward UHC? Affordability and cost effectiveness Equitable Access: means different things to different people: acceptability - patients/ consumer education & provider engagement, reliability availability = physical, geographic, equity, economic/ affordability, staff capacity and competence, access to appropriate/ high value services, meeting community needs and values, new approaches to address gaps and needs Quality service provision and good systems to deliver services (Appropriate and rational use of medicines) Achieving clinical outcomes (should have minimum package of care)

What are the objectives of medicines benefit policies and programs on the path toward UHC? Systems (capable to implement now & strength over time) Safety Non traditional supply mechanisms Idea of social solidarity Needs good governance Should have acceptable minimum package of care Engage political support Confidence in system and trust/ satisfaction with care – “meeting community needs” Political objectives and timing Managing public/ private interface Private aligning with public Know disease profile in country (country specific context) Matching with national health strategy Sustainability Monitoring as a way of continuous improvement Good systems to deliver healthcare services Availability - procurement

How to set priorities for selection of medicines Traditional medicines/ complimentary & fund for ‘unusual’ needs - need to be aware of needs Cost effective (pharmaco- economic approaches, including use in practice) STGs, protocols Organisational capacity to use and deliver “Essential” medicines - high value and special needs Budget impact Risk sharing OP/ IP balancing acts (IP considered catastrophic, private: greater IP benefit, hidden cost of recurrent OP costs, prevention of NCDs) Epidemiological profile – disease patterns Medicines that reduce other healthcare costs “Health balance sheet” of investment – longer term prevention Allowing innivators Appropriate incentives – goals Manage stakeholder expectations Local industry capabilities

Unintended Impacts “Abuse” – managing clinical and financial, outsourcing to private sector, investigations Market forces change Loss of clinical goals – treat to payments Waste of resources Focus on activities with incentives Providers/ manufacturers lose interest (not subsidised) Collusion to take advantage - monitoring essential Political interference - “promises”/ media pressure Risk sub-standard products (low price) Poor buy- in by providers and patients Limited choice Increased access - risk AMR/ poor RUM Loss of overall goals - poor alignment